[2]
Gaw A, Packard CJ, Lindsay GM, Murray EF, Griffin BA, Caslake MJ, Colquhoun I, Wheatley DJ, Lorimer AR, Shepherd J. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Arteriosclerosis, thrombosis, and vascular biology. 1996 Feb:16(2):236-49
[PubMed PMID: 8620338]
[3]
Insull W Jr, Davidson MH, Demke DM, Dujovne CA, Eckert SM, Ginsberg D, Goldberg AC, Hodis HN, Hughes TA, Kane JP. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. Atherosclerosis. 1995 Jan 20:112(2):223-35
[PubMed PMID: 7772081]
[4]
McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatric research. 2002 Jun:51(6):715-21
[PubMed PMID: 12032266]
Level 1 (high-level) evidence
[5]
Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19:257(23):3233-40
[PubMed PMID: 3295315]
[6]
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. Journal of clinical lipidology. 2015 Mar-Apr:9(2):129-69. doi: 10.1016/j.jacl.2015.02.003. Epub 2015 Apr 7
[PubMed PMID: 25911072]
[7]
Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA, NLA Expert Panel. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of clinical lipidology. 2015 Nov-Dec:9(6 Suppl):S1-122.e1. doi: 10.1016/j.jacl.2015.09.002. Epub 2015 Sep 18
[PubMed PMID: 26699442]
[8]
Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U. Statins for children with familial hypercholesterolemia. The Cochrane database of systematic reviews. 2019 Nov 7:2019(11):. doi: 10.1002/14651858.CD006401.pub5. Epub 2019 Nov 7
[PubMed PMID: 31696945]
Level 1 (high-level) evidence
[9]
Lozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, Anderson ML, Whitlock E. Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force. 2016 Aug:():
[PubMed PMID: 27559556]
Level 1 (high-level) evidence
[10]
Scaldaferri F, Pizzoferrato M, Ponziani FR, Gasbarrini G, Gasbarrini A. Use and indications of cholestyramine and bile acid sequestrants. Internal and emergency medicine. 2013 Apr:8(3):205-10. doi: 10.1007/s11739-011-0653-0. Epub 2011 Jul 8
[PubMed PMID: 21739227]
[11]
Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clinics in liver disease. 2012 May:16(2):331-46. doi: 10.1016/j.cld.2012.03.010. Epub
[PubMed PMID: 22541702]
[12]
Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.). 2019 Jan:69(1):394-419. doi: 10.1002/hep.30145. Epub 2018 Nov 6
[PubMed PMID: 30070375]
[13]
Hagag P, Nissenbaum H, Weiss M. Role of colestipol in the treatment of hyperthyroidism. Journal of endocrinological investigation. 1998 Dec:21(11):725-31
[PubMed PMID: 9972670]
[14]
Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut. 2015 Jan:64(1):84-92. doi: 10.1136/gutjnl-2013-305965. Epub 2014 Apr 12
[PubMed PMID: 24727487]
[15]
Farrugia A, Arasaradnam R. Bile acid diarrhoea: pathophysiology, diagnosis and management. Frontline gastroenterology. 2021:12(6):500-507. doi: 10.1136/flgastro-2020-101436. Epub 2020 Sep 22
[PubMed PMID: 34712468]
[16]
Payne VW, Secter RA, Noback RK. Use of colestipol in a patient with digoxin intoxication. Drug intelligence & clinical pharmacy. 1981 Nov:15(11):902-3
[PubMed PMID: 7297421]
[17]
Hood CJ, Wolley MJ, Kam AL, Kendrik-Jones JC, Marshall MR. Feasibility study of colestipol as an oral phosphate binder in hemodialysis patients. Nephrology (Carlton, Vic.). 2015 Apr:20(4):250-6. doi: 10.1111/nep.12388. Epub
[PubMed PMID: 25557531]
Level 2 (mid-level) evidence
[18]
Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia. Drugs. 1980 Mar:19(3):161-80
[PubMed PMID: 6988203]
[19]
McGlone ER, Bloom SR. Bile acids and the metabolic syndrome. Annals of clinical biochemistry. 2019 May:56(3):326-337. doi: 10.1177/0004563218817798. Epub 2019 Mar 4
[PubMed PMID: 30453753]
[20]
Ebhohon E, Chung RT. Systematic review: efficacy of therapies for cholestatic pruritus. Therapeutic advances in gastroenterology. 2023:16():17562848231172829. doi: 10.1177/17562848231172829. Epub 2023 May 25
[PubMed PMID: 37255856]
Level 1 (high-level) evidence
[21]
Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Feingold KR. Cholesterol Lowering Drugs. Endotext. 2000:():
[PubMed PMID: 27809434]
[22]
Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. The American journal of cardiology. 2007 Mar 19:99(6A):47C-55C
[PubMed PMID: 17368279]
[23]
Halpern DG, Weinberg CR, Pinnelas R, Mehta-Lee S, Economy KE, Valente AM. Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2019 Feb 5:73(4):457-476. doi: 10.1016/j.jacc.2018.10.075. Epub
[PubMed PMID: 30704579]
[25]
Steinmetz KL. Colesevelam hydrochloride. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2002 May 15:59(10):932-9
[PubMed PMID: 12040732]
[26]
Arnold MA, Swanson BJ, Crowder CD, Frankel WL, Lam-Himlin D, Singhi AD, Stanich PP, Arnold CA. Colesevelam and colestipol: novel medication resins in the gastrointestinal tract. The American journal of surgical pathology. 2014 Nov:38(11):1530-7. doi: 10.1097/PAS.0000000000000260. Epub
[PubMed PMID: 24921636]
[27]
Lin S, Sanders DS, Gleeson JT, Osborne C, Messham L, Kurien M. Long-term outcomes in patients diagnosed with bile-acid diarrhoea. European journal of gastroenterology & hepatology. 2016 Feb:28(2):240-5. doi: 10.1097/MEG.0000000000000541. Epub
[PubMed PMID: 26636406]
[28]
Sirmans SM, Beck JK, Banh HL, Freeman DA. Colestipol-induced hepatotoxicity. Pharmacotherapy. 2001 Apr:21(4):513-6
[PubMed PMID: 11310528]
[29]
Witztum JL, Jacobs LS, Schonfeld G. Thyroid hormone and thyrotropin levels in patients placed on colestipol hydrochloride. The Journal of clinical endocrinology and metabolism. 1978 May:46(5):838-40
[PubMed PMID: 262768]
[30]
Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics. 1980 Feb:65(2):243-50
[PubMed PMID: 7354970]
[32]
Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of clinical lipidology. 2011 May-Jun:5(3):133-140. doi: 10.1016/j.jacl.2011.03.001. Epub 2011 Mar 11
[PubMed PMID: 21600517]
[33]
Jones LK, McMinn M, Kann D, Lesko M, Sturm AC, Walters N, Chen N, Fry K, Brownson RC, Gidding SS, Williams MS, Rahm AK. Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis. Implementation science communications. 2021 Mar 19:2(1):32. doi: 10.1186/s43058-021-00135-8. Epub 2021 Mar 19
[PubMed PMID: 33741054]